Biotest AG
BIESF · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $1 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $1 | $0 | $1 |
| Enterprise Value | $1 | $2 | $1 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -39% | 35% | -3.9% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 11.4% | 26% | 19.4% | 32.6% |
| EBITDA | -$0 | $0 | $0 | $0 |
| % Margin | -7.7% | 5.8% | 1.5% | 22.2% |
| Net Income | -$0 | -$0 | -$0 | $0 |
| % Margin | -17.2% | -1.7% | -6.2% | 6.2% |
| EPS Diluted | -0.55 | -0.094 | -0.25 | 0.24 |
| % Growth | -485.1% | 62.4% | -204.2% | – |
| Operating Cash Flow | – | $0 | -$0 | $0 |
| Capital Expenditures | – | $0 | $0 | $0 |
| Free Cash Flow | – | $0 | -$0 | $0 |